Clinical Trial Update: Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating gemcitabine plus trastuzumab versus capecitabine plus trastuzumab in HER-2 positive metastatic breast cancer has been terminated, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• HERCEPTIN (trastuzumab)
• Xeloda (capecitabine)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Breast Cancer | Phase 3 | Status: TERMINATED